T-cell Phenotypes Associated with Clinical Response to Adoptive Immunotherapy

Technology Bundle IDNCI-E-167-2019 T-cell Phenotypes Associated with Clinical Response to Adoptive ImmunotherapyApplicationsTherapeuticsLead InventorsSteven Rosenberg (NCI)Co-InventorsFrank Lowery (NCI)Gregoire Altan-Bonnet (NCI)Paul Robbins (NCI)Sri Krishna (NCI)Development StatusBasic (Target Identification)ICsNCIAdoptive T-cell therapy (ACT) utilizes tumor-reactive T cells to induce disease remission. While ACT has been used effectively to treat metastatic melanoma and certain epithelial cancers, most patients do not respond to treatment. Although the mechanisms underlying this variable response to therapy are not fully elucidated, the phenotype of the adoptively transferred cell is known to be a key determinant of treatment efficacy.Researchers at National Cancer Institute ’s (NCI) Surgery Branch have now determined that the CD3+CD39-CD69- subpopulation of T cells are highly associated with complete disease response following ACT. Leveraging over 30 years of ACT clinical data and associated biological materials, NCI researchers immune-profiled archived infusion products and correlated cell phenotypes with therapeutic outcomes. Clustering of clinically significant markers helped in determining the candidate profile. Validation of the markers in other patients and other cancer settings is ongoing.The inventive method could be used to engineer relevant cell therapy products in multiple disease settings, including, but not limited to, cancer and acute and chronic infectiou...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research